Table 6.
Variations for one-way sensitivity analysis
| Parameters | Base case | Distribution | Min | Max | Source |
|---|---|---|---|---|---|
| Length of WW after 2nd line in months | 18.56 | t-Distribution | 8.69 | 28.43 | A nationwide survey among 202 Japanese hematologists |
| Length of treatment period of ibrutinib in months | 31.00 | Normal distribution | 26.65 | 35.35 | Byrd et al. [13] |
| Length of 3rd line treatment in months | 2.94 | t-Distribution | 1.96 | 3.93 | A nationwide survey among 202 Japanese hematologists |
| Length of 2nd line treatment in months | 5.15 | t-Distribution | 3.79 | 6.50 | A nationwide survey among 202 Japanese hematologists |
| Length of hospital stay for FCR treatment | 8.00 | =/− 20% of mean value | 6.40 | 9.60 | Expert opinion |
| Number of CLL patients | 2000 | =/− 20% of mean value | 1600 | 2400 | Ministry of Health, Labor and Welfare [12]. |
WW watch and wait, FCR fludarabine, cyclophosphamide, rituximab